APLM
Apollomics Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.05
+4.49%Year over year
Reported trailing growth
- Revenue
- +4192.9%
- EBITDA
- +77.0%
- EBIT
- +77.5%
- EPS
- +86.1%
- Free cash flow
- +37.5%
- Operating cash flow
- +37.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +197.4%
- EBITDA
- +77.4%
- EBIT
- +77.5%
- Net income
- +79.7%
- EPS
- +85.7%
- Free cash flow
- +64.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025